Theravance Biopharma, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Theravance Biopharma, Inc. (TBPH) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$255.73 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-28
- Theravance Biopharma, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$2.32M, a 100.90% decline year-over-year.
- Theravance Biopharma, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$48.33M.
- Theravance Biopharma, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was $258.14M.
- Theravance Biopharma, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$61.79M.
- Theravance Biopharma, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$255.73M, a 210.23% decline from fiscal 2016.
- Theravance Biopharma, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $232.00M, a 887.58% increase from fiscal 2015.
- Theravance Biopharma, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $23.49M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$50.65M derived: sum of 2 quarters · filed 2018-02-28 | -$255.73M 10-K · filed 2018-02-28 | |
| 2017-09-30 | -$48.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$253.41M 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | -$205.08M 10-Q · filed 2017-08-09 | |||
| 2016-12-31 | $258.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $196.35M derived: sum of 2 quarters · filed 2018-02-28 | $232.00M 10-K · filed 2018-02-28 | |
| 2016-09-30 | -$61.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$26.14M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $35.66M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $23.49M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |